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The kinaseMnk2 is a substrate of the MAPK pathway
and phosphorylates the translation initiation factor
eIF4E. In humans, MKNK2, the gene encoding for
Mnk2, is alternatively spliced yielding two splicing
isoformswith differing last exons:Mnk2a, which con-
tains a MAPK-binding domain, and Mnk2b, which
lacks it. We found that the Mnk2a isoform is down-
regulated in breast, lung, and colon tumors and is
tumor suppressive. Mnk2a directly interacts
with, phosphorylates, activates, and translocates
p38a-MAPK into the nucleus, leading to activation
of its target genes, increasing cell death and sup-
pression of Ras-induced transformation. Alterna-
tively, Mnk2b is pro-oncogenic and does not activate
p38-MAPK, while still enhancing eIF4E phosphoryla-
tion. We further show that Mnk2a colocalization with
p38a-MAPK in the nucleus is both required and
sufficient for its tumor-suppressive activity. Thus,
Mnk2a downregulation by alternative splicing is a
tumor suppressor mechanism that is lost in some
breast, lung, and colon tumors.
INTRODUCTION
The serine/threonine kinases Mnk1 and Mnk2 were discovered
by their direct interaction with and activation by the mitogen-
activated protein kinases (MAPKs) extracellular signal-regulatedkinase (ERK) and p38-MAPK (Fukunaga and Hunter, 1997; Was-
kiewicz et al., 1997). Mnk1 and Mnk2 phosphorylate the transla-
tion initiation factor eIF4E on serine 209 (Fukunaga and Hunter,
1997; Waskiewicz et al., 1997). The eIF4E protein binds to the
50 cap structure of mRNAs and is essential for cap-dependent
translational initiation (Mamane et al., 2004). In mice lacking
both kinases (MNK-double-knockout [DKO] mice), eIF4E is
completely unphosphorylated on serine 209 (Shenberger et al.,
2007; Ueda et al., 2004). Intriguingly, these mice develop and
live normally, displaying no adverse phenotype (Shenberger
et al., 2007; Ueda et al., 2004). Mnk1 andMnk2 are 72% identical
in their amino acid sequence (Fukunaga and Hunter, 1997; Was-
kiewicz et al., 1997). Biochemically, it has been shown that
whereas Mnk1 activation is dependent on upstream MAPK
signaling, Mnk2 possesses intrinsic basal activity when intro-
duced into cells (Scheper et al., 2003). There is limited evidence
connecting Mnk1/Mnk2 to human cancer, none directly. For
example, Mnk1 was shown to be downregulated during differen-
tiation of hematopoietic cells and upregulated in lymphomas
(Worch et al., 2004). In a functional study, overexpression of a
constitutively active Mnk1 mutant, or a phosphomimetic eIF4E
mutant, promoted c-Myc-mediated lymphomagenesis in vivo
(Wendel et al., 2007). Recently, it has been demonstrated that
mice lacking both Mnk1 and Mnk2 are more resistant to tumor
development when crossed with phosphatase and tensin homo-
log (PTEN/) mice, and mouse embryonic fibroblast (MEF) cells
from these mice are resistant to transformation by several onco-
genes, suggesting that eIF4E phosphorylation or the presence of
at least one Mnk is required for transformation (Furic et al., 2010;
Ueda et al., 2010). The notion that Mnk1 and Mnk2 are positive
drivers in human cancer stems from the important role theirCell Reports 7, 501–513, April 24, 2014 ª2014 The Authors 501
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Figure 1. A Switch in MKNK2 Alternative
Splicing in Primary Tumors and Cancer
Cell Lines
(A) The human-splicing isoforms of MKNK2
contain a basic region important for eIF4G binding
in their N terminus as well as a putative NLS. The
catalytic domain contains two conserved threo-
nine residues (T197 and T202) in the activation
loop that need to be phosphorylated (P) by MAP
kinases for kinase activation (Scheper et al., 2003).
Mnk2a contains a binding site for MAP kinases
located in the C terminus (Scheper et al., 2003).
Mnk2b is generated by an alternative 30 splice site
in intron 14 that generates a shorter last exon
(14b), lacking the MAPK-binding site (Scheper
et al., 2003).
(B) RNA levels of Mnk2a and Mnk2b in the indi-
cated primary or immortal breast and breast
cancer cell lines.
(C) The ratios of Mnk2a/Mnk2b RNA in non-
transformed breast cell lines (n = 4) and breast
tumor samples (n = 13) are represented by a box
plot. Top and bottom box edges represent the
third and first quartile. Whiskers indicate 90th and
10th percentiles; yellow and blue dots represent
minimum and maximum points, respectively. p
value is based on t test two-tailed analysis.
(D) RNA levels of SRSF1 in breast tumor samples
(n = 13) and nontransformed breast cell lines (n = 4)
are represented by a box plot as depicted in (C).
Median SRSF1 levels from nontransformed breast
cell lines (4) and breast tumor samples (13) are
shown. p value is based on t test two-tailed anal-
ysis.
(E–G) Pie chart representation of percentage (%) of
normal and tumor breast (E), lung (F), and colon (G)
samples with Mnk2a/Mnk2b ratios %1 (yellow
color) or >1 (blue color). Analysis is based on RNA-
seq data from TCGA project (https://tcga-data.nci.
nih.gov/tcga/).known substrate, eIF4E, plays in cancer (Mamane et al., 2004),
and not from direct functional evidence.
In humans, each of the MKNK1 and MKNK2 genes gives rise
to at least two distinct proteins, with different C termini, as a
consequence of 30 prime alternative splicing (Parra-Palau et al.,
2003; Parra et al., 2005; Scheper et al., 2003). The longer forms
of human Mnk1 and Mnk2, referred to as Mnk1a and Mnk2a,
respectively, possess a MAPK-binding motif that is absent
from the shorter isoforms Mnk1b andMnk2b. In the correspond-
ing murine proteins, no short forms have yet been identified
(Parra et al., 2005). A recent study showed that resistance of
pancreatic cancer cells to gemcitabine is mediated by SRSF1
upregulation and a switch in Mnk2 alternative splicing, which
enhances eIF4E phosphorylation, implicating this alternative
splicing event with chemotherapy resistance (Adesso et al.,
2013).
Here, we examined the expression of Mnk2-splicing isoforms
in several types of cancer and manipulated the expression of
each isoform in normal and transformed cells. We found that
the Mnk2a isoform is downregulated in human cancers and is502 Cell Reports 7, 501–513, April 24, 2014 ª2014 The Authorsa tumor suppressor, which colocalizes, interacts with, phosphor-
ylates, and activates p38-MAPK, leading to activation of its
target genes and to p38a-mediated cell death. These results
suggest that Mnk2a is a p38-MAPK kinase and acts as an up-
stream activator of p38-MAPK. Moreover, Mnk2a antagonizes
Ras-induced transformation in vitro and in vivo. However, the
Mnk2b isoform, or an inactive kinase-dead version of Mnk2a
(Mnk2aKD), did not activate the p38-MAPK pathway and was
pro-oncogenic. Taken together, our results suggest that Mnk2
alternative splicing serves as a switch in several cancers to
downregulate a tumor suppressor isoform (Mnk2a) that activates
the p38-MAPK stress pathway and to induce an isoform (Mnk2b)
that does not activate this pathway and is pro-oncogenic.
RESULTS
A Switch inMKNK2 Alternative Splicing in Breast, Lung,
and Colon Cancers
MKNK2 is alternatively spliced to yield two isoforms: Mnk2a and
Mnk2b (Figure 1A) (Parra-Palau et al., 2003; Parra et al., 2005;
Scheper et al., 2003). Recently, we have found that the splicing
factor oncoprotein SRSF1 (SF2/ASF) modulates the splicing of
MKNK2, to reduce Mnk2a and increase Mnk2b (Karni et al.,
2007). To examine if changes in MKNK2 splicing are a general
phenomenon in cancer, we compared immortal and primary
breast cells to breast cancer cell lines, as well as to breast tumor
samples. We detected higher or equal expression of Mnk2a
compared to Mnk2b in immortal (MCF-10A, HMLE, HMT-3522-
S1) (Itoh et al., 2007) and primary breast cells (human mammary
epithelial cells). In contrast, Mnk2a expression was significantly
decreased, and in some cases, Mnk2b increased in tumor cell
lines and tumor samples (Figures 1B, 1C, and S1A). In most of
these tumors, SRSF1 was elevated (Figure 1D). To expand our
analysis, we analyzed RNA-sequencing (RNA-seq) data from
normal and cancer samples available from The Cancer Genome
Atlas (TCGA) project (https://tcga-data.nci.nih.gov/tcga/). Com-
parison of reads covering Mnk2a or Mnk2b splice junctions in
these samples shows that whereas only two out of 106 (1.9%)
normal breast samples have a Mnk2a/Mnk2b ratio equal to or
less than 1:1, 104 out of 994 (10.5%) breast tumor samples
have such a ratio. This trend is also observed in lung and colon
samples (Figures 1E–1G). In normal lung samples, Mnk2a level
was higher and Mnk2b level was lower compared to lung tumors
(Figures S2A–S2C). In the samemanner, the Mnk2a/Mnk2b ratio
in normal colon samples was higher compared to colon tumors
(Figure S2E). These results suggest that a ratio of Mnk2a/
Mnk2b less than 1:1, due to either reduced levels of Mnk2a
and/or increased levels of Mnk2b, is much more prevalent in
tumors than in normal tissue samples. We also examined the
correlation of expression of several serine/arginine-rich (SR)
and heterogeneous nuclear ribonucleoprotein (hnRNP) proteins
with Mnk2a/Mnk2b ratios. We found that in breast tumors,
expression of several SR and hnRNP A/B proteins (SRSF1,
SRSF2, SRSF3, SRSF4, SRSF7, SRSF9, hnRNP A1, hnRNP
A2/B1, and Tra2b) had a negative correlation (Pearson correla-
tion smaller than 0.1) with Mnk2a/Mnk2b ratios. Expression
of SRSF5 had a positive correlation with Mnk2a/Mnk2b ratios,
whereas expression of SRSF6 had no correlation (Table S1).
We found a similar, but not identical, pattern in lung and colon
tumors (Tables S2 and S3). Expression of the factors that
showed negative correlation with Mnk2a/Mnk2b ratios was
also elevated in breast tumors that showed aMnk2a/Mnk2b ratio
equal to or less than 1:1 (Figure S1I) and in lung and colon tumors
when compared to corresponding normal tissues (Figures S2D
and S2F).
To examine if oncogenic transformation affects MKNK2
splicing, we compared MCF-10A cells to MCF-10A cells trans-
formed by a mutant Ras oncogene (H-RasV12). We found that
oncogenic Ras reduced Mnk2a and elevated Mnk2b as well as
SRSF1 expression (Figures S1B and S1C). Similarly, pancreatic
cancer cell lines harboring mutant K-Ras showed reduced
Mnk2a and elevated Mnk2b levels compared to pancreatic
cancer cell lines with wild-type (WT) K-Ras (Figure S1D). The
pancreatic cancer cell line Panc-1, which harbors a K-Rasmuta-
tion, showed elevated levels of SRSF1 and Mnk2b and reduced
Mnk2a at both the RNA and protein levels compared to BXPC-3
cells harboring WT K-Ras (Figures S1E–S1G). This altered
splicing is also shown in another oncogenic-transformationmodel: immortal lung epithelial cells (BEAS-2B) transformed
by SRSF1 (Shimoni-Sebag et al., 2013) (Figure S1H). These
data suggest that oncogenic transformation, caused either by
activated Ras or another oncogene, affects MKNK2 alternative
splicing.
Mnk2a Has Tumor-Suppressive Activity, whereas
Mnk2b Is Pro-oncogenic In Vitro
To examine the role of Mnk2 alternative splicing in cellular trans-
formation, we seeded nontransformed breast MCF-10A cells
transduced with Mnk2-splicing isoforms into soft agar. Cells
expressing Mnk2b or a Mnk2aKD were transformed and gener-
ated colonies in soft agar, whereas cells expressing Mnk2a did
not (Figures 2A and 2C). Mnk2aKD probably acts in a domi-
nant-negative manner by competing with Mnk2a for substrate
binding, while incapable of phosphorylation. Similar results
were obtained in another transformation model of NIH 3T3 cells
(Figures S3A and S3B). Furthermore, when MCF-10A cells
expressing Mnk2-splicing isoforms were transformed by onco-
genic Ras, cells coexpressing Mnk2a showed reduced ability to
form colonies in soft agar, indicating that Mnk2a can block Ras-
induced transformation (Figures 2B and 2D). Similarly, Mnk2a in-
hibited colony formation in soft agar of the osteosarcoma cell line
U2OS (Figures S3C and S3D). Knockdown of Mnk2a enhanced
colony formation of MCF-10A and NCI-H460 cells in soft agar,
suggesting that Mnk2a is tumor suppressive (Figures S3E–
S3H). Neither Mnk2a nor Mnk2b expression changed signifi-
cantly cell proliferation or cell-cycle distribution (Figures S3I–
S3N).However, cellswithMnk2aknockdownhadaslightlyhigher
proliferation rate, indicating that Mnk2a reduction may enhance
proliferation (Figure S3J). Taken together, these results suggest
that the tumor-suppressive activity of Mnk2a is probably only
partly mediated through its effects on cellular proliferation.
Mnk2a Has a Tumor Suppressor Activity In Vivo
In order to examine if Mnk2a possesses tumor suppressor
activity in vivo, we injected Ras-transformed MCF-10A cells
transduced with Mnk2-splicing isoforms into nonobese dia-
betic-severe combined immunodeficiency (NOD-SCID) mice.
We found that mice injected with Ras-MCF-10A cells expressing
either empty vector or Mnk2b formed tumors (six out of six),
whereas mice injected with Ras-MCF-10A cells expressing
Mnk2a did not form any tumors (zero out of eight) (Figure 2E).
Tumors from cells expressing Mnk2b showed an increased
mitotic index (Figures 2G and 2H) compared with tumors from
cells expressing Ras alone but did not show significant
enhanced tumor growth (Figure 2E). Inversely, mice injected
with Ras-MCF-10A cells expressing small hairpin RNA (shRNA)
against Mnk2a showed enhanced tumor growth rate (Figure 2F)
and increased mitotic index in the tumors (Figures 2I and 2J),
indicating that Mnk2a depletion cooperates with and enhances
Ras tumorigenicity. Collectively, our results suggest that
Mnk2a has tumor suppressor activity, and it can antagonize
Ras-mediated transformation in vitro and in vivo.
Mnk2a Sensitizes Cells to Stress-Induced Cell Death
Because overexpression or downregulation of Mnk2a did not
affect cellular proliferation significantly (Figures S3I–S3N), weCell Reports 7, 501–513, April 24, 2014 ª2014 The Authors 503
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Figure 2. Mnk2a Inhibits Ras-Induced
Transformation and Tumorigenesis
(A) Western blot of MCF-10A cells transduced
with the indicated retroviruses encoding for Mnk2
isoforms and Mnk2aKD.
(B) Western blot of cells described in (A)
transduced with a retrovirus encoding for
H-RASV12.
(C) Cells described in (A) were seeded into soft
agar (see Experimental Procedures) in duplicates,
and colonies were allowed to grow for 14 days.
Colonies in ten fields of each well were counted,
and the mean and SD of colonies per well of three
wells are shown (n = 3).
(D) Cells described in (B) were seeded into soft
agar and counted as in (C) (n = 3).
(E and F) Pools of MCF-10A cells transformed with
the indicated retroviruses encoding Mnk2 iso-
forms followed by H-RASV12 transduction (E) or
MCF-10A cells transduced with shRNA against
Mnk2a (Sh2a-2) followed by transformation by
H-RASV12 (F) were injected (23 106 cells/injection,
in Matrigel) subcutaneously into NOD-SCID
mice. Tumor growth curves were calculated as
described in Experimental Procedures. The num-
ber of tumors formed per injection is shown near
the legend bars. *p% 0.01.
(G–J) Formalin-fixed, paraffin-embedded tissue
sections from tumors derived from the indicated
cell pools described in (E) and (F) were stained with
anti-phospho-H3 to detect mitotic cells (G and I).
Graphs show the average and SD of p-H3-positive
cells from ten fields of three different tumors (H
and J). *p% 0.01.hypothesized that Mnk2a might enhance the sensitivity of cells
to apoptosis. To examine the possible role of Mnk2-splicing
isoforms in the response to cellular stress, we challenged
immortalized breast cells (MCF-10A and Ras-transformed
MCF-10A cells) transduced with retroviruses encoding Mnk2a,
Mnk2b, or Mnk2aKD with different stress conditions. Although
Mnk2a enhanced apoptotic cell death in response to anisomycin
treatment, as measured by trypan blue exclusion and caspase-3
cleavage, Mnk2b and the Mnk2aKD protected against
apoptosis (Figures 3A and 3D). Moreover, knockdown of
Mnk2a protected MCF-10A cells from anisomycin-induced
apoptosis (Figures 3B and 3E). The correlation of apoptosis
and caspase-3 cleavage with p38-MAPK phosphorylation
(Figures 3D and 3E) suggests that Mnk2a proapoptotic activity
might involve activation of the p38-MAPK pathway. Mnk2a
also reduced survival of Ras-transformed MCF-10A cells504 Cell Reports 7, 501–513, April 24, 2014 ª2014 The Authorsand MCF-10A cells forced to grow in
suspension or stimulated with osmotic
shock (Figures S4A and S4C). In contrast,
knockdown of Mnk2a protected cells
from osmotic shock, suggesting that
Mnk2a mediated this stress response
(Figure S4D). Mnk2a also inhibited
the survival of MCF-10A cells trans-
formed by oncogenic Ras when sparselyseeded for colony survival assay (Figures 3C and 3F), sug-
gesting that Mnk2a sensitizes Ras-transformed cells to
low-density stress conditions. One of the stress pathways
induced by anisomycin and other cellular insults is the
p38-MAPK pathway (Benhar et al., 2001; Cuadrado and
Nebreda, 2010; Hazzalin et al., 1996). In order to examine
if p38-MAPK activation is involved in Mnk2a-enhanced cell
death, we blocked p38-MAPK kinase activity with the
specific kinase inhibitor ATP competitor SB203580 (Badger
et al., 1996; Benhar et al., 2001; Lee et al., 2000). p38-MAPK
inhibition partially rescued cells expressing Mnk2a from ani-
somycin-induced cell death (Figure S4B). Neither transient
expression nor stable expression of Mnk2a alone reduced
survival of MCF-10A cells, suggesting that Mnk2a exerts its
proapoptotic properties only under stress conditions (Figures
S4F and S4G).
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Figure 3. Mnk2a Sensitizes MCF-10A Cells
to Stress-Induced Apoptosis
(A and B) Trypan blue exclusion assay of MCF-10A
cells transduced by the indicated retroviruses.
Following 24 hr in growth factor-free media, cells
were treated with 0.5 mM anisomycin for 24 hr (A)
or 48 hr (B). *p% 0.05; **p% 0.01.
(C) Colony formation assay of pools of MCF-10A
cells transduced with the indicated retroviruses
encoding Mnk2 isoforms and transformed by
H-RASV12. Average and SD of the number of col-
onies per well are shown (n = 3). *p% 0.05.
(D and E) Cells described in (A) and (B) were
analyzed by western blot. Cleaved caspase-3
served as a marker for apoptosis. Levels of p-p38,
p38, p-eIF4E, and eIF4E were detected with the
indicated antibodies. b-catenin served as loading
control. Numbers represent ratios of p-p38/total
p38 and p-eIF4E/total eIF4E normalized to that of
pBABE or MLP (arbitrarily set at 1) ± SD (n = 3).
(F) Representative wells with colonies described
in (C).
(G) MCF-10A cells transduced with the indicated
retroviruses followed by transduction with
H-RASV12 were seeded into soft agar in the pres-
ence or absence of the indicated concentrations of
SB203580, and colonies were counted 14 days
later. *p% 0.01; **p% 0.05 (n = 3).
(H) Photographs of representative fields of col-
onies in soft agar obtained as described in (G).Mnk2a, but Not Mnk2b, Enhances p38a-Mediated Cell
Death and Suppression of Ras-Induced Transformation
Because Mnk2a, but not Mnk2b, contains a MAPK-binding
domain (Figure 1A) and can be activated by ERK and p38-
MAPK (Parra et al., 2005; Scheper et al., 2003), we examined if
Mnk2a can mediate stress responses emanating from activated
p38-MAPK. MCF-10A cells expressing either Mnk2 isoforms or
knocked down for Mnk2a were transduced with a constitutively
active p38amutant (Askari et al., 2007; Avitzour et al., 2007; Dis-
kin et al., 2004) and grown in the absence or presence of the p38Cell Reports 7, 501–5kinase inhibitor SB203580. Cells express-
ing Mnk2a showed increased cell death
upon active p38-MAPK transduction,
which was inhibited by SB203580 (Fig-
ures S5A and S5B). Cells in which
Mnk2a was knocked down showed
increased protection from p38-induced
cell death (Figures S5C and S5D).
SB203580 efficiently inhibited p38
activity, as was measured by phosphory-
lation of its substrate MK2. However, it
did not affect phosphorylation of p38-
MAPK or eIF4E, indicating that
SB203580 treatment did not inhibit up-
stream Mnk2 or MKK3/MKK6 activity
(Figure S5E). These results suggest that
Mnk2a augments p38-MAPK stress
activity. Inhibition of p38-MAPK by
SB203580 rescued the ability of cellscotransduced with Mnk2a and Ras to form colonies in soft
agar, suggesting that p38 activation by Mnk2a plays an impor-
tant role in its ability to suppress Ras-induced transformation
(Figures 3G and 3H).
Mnk2a Interacts with, Activates, and Induces Nuclear
Translocation of p38-MAPK
To determine if Mnk2a activates p38-MAPK, we examined
the phosphorylation status of p38-MAPK in cells expressing
Mnk2-splicing isoforms (Enslen et al., 1998). As expected,13, April 24, 2014 ª2014 The Authors 505
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Figure 4. Mnk2a Interacts with p38-MAPK
and Leads to Its Activation and Transloca-
tion into the Nucleus
(A) Western blot analysis of MCF-10A cells trans-
duced with the indicated retroviruses encoding for
Mnk2 isoforms or Mnk2aKD. Numbers represent
the ratios of p-p38/total p38 and p-eIF4E/total
eIF4E normalized to pBABE (arbitrarily set at 1) ±
SD (n = 3).
(B) Coimmunoprecipitation of HA-p38a or T7-
Mnk2 isoforms from HEK293 cells cotransfected
with the indicated Mnk2 isoforms together with
HA-p38a-MAPK. Precipitated and input proteins
were subjected to western blot analysis. The
asterisk (*) represents a nonspecific band. As a
control, lysate from cells transfected with T7-
Mnk2a was incubated with beads in the absence
of the T7 antibody. IP, immunoprecipitation; IB,
immunoblotting.
(C) Western blot analysis of HeLa cells co-
transfected with either Mnk2a or MKK3 together
with HA-p38a-MAPK. b-catenin was used as a
loading control.
(D) Left: western blot analysis of MEF cells from
WT mice (MKK3/MKK6 WT) and MKK3/MKK6/
DKO mice. Right shows a western blot analysis of
MEF cells from MKK3/MKK6/ DKO mice (MEF
MKK3/MKK6/) transduced with the indicated
retroviruses. b-catenin was used as a loading
control.
(E) In vitro kinase assay using recombinant Mnk2a,
recombinant kinase dead (KD) p38a, recombinant
eIF4E alone, or in the indicated combinations.
Reaction mixes were stopped, separated on
SDS-PAGE, and transferred onto nitrocellulose
membranes. Upper panel shows a radioactive
exposure of the membrane detected by a Fuji
phosphorimager cassette and visualized by
MacBass phosphorimager. Bottom panel shows
the same membrane as above that was probed
with the indicated antibodies and detected by
enhanced chemiluminescence.
(F) Cellular distribution of p38a in MCF-10A cells,
transduced with retroviruses encoding the indi-
cated Mnk2 isoforms. N, nuclear fraction; C,
cytoplasmic fraction. c-myc (nuclear) and
caspase-2 (cytoplasmic) served as fractionation
controls.phosphorylation of a known substrate of Mnk2, serine 209 of
eIF4E, was induced by Mnk2a expression (Figures 4A, S3A,
and S3C). Although previous reports have suggested that
Mnk2b has a lower kinase activity than Mnk2a (Scheper et al.,
2003), we observed that it phosphorylates eIF4E to a similar
extent asMnk2a (Figures 4A, S3A, SC3, and S5E). TheMnk2aKD
did not enhance eIF4E phosphorylation (Figures 4A, S3A, and
S3C). In contrast, only cells expressing Mnk2a showed
increased p38-MAPK phosphorylation, suggesting that p38-
MAPK is activated by Mnk2a (Figures 4A, 4C, 4D, S5E, and
S6A) (Avitzour et al., 2007; Enslen et al., 1998). Moreover, knock-
down of Mnk2a in MCF-10A cells reduced p38-MAPK basal
phosphorylation level (Figures 3E and S3E). In addition, we
determined that the phosphorylation state of the p38-MAPK
substrate MK2 was enhanced only in cells expressing Mnk2a,506 Cell Reports 7, 501–513, April 24, 2014 ª2014 The Authorsbut not Mnk2b or Mnk2aKD (Figure 4A). Knockdown of Mnk2a
inhibited MK2 phosphorylation, and inhibition of p38-MAPK by
the kinase inhibitor SB203580 abolished MK2 phosphorylation
in cells expressing Mnk2a (Figure S5E). To further examine if
the kinase activity of Mnk2a is important for p38 phosphoryla-
tion, we treated MCF-10A cells with the Mnk1/Mnk2 kinase in-
hibitor CGP 57380 (Knauf et al., 2001) (Chrestensen et al.,
2007). Mnk1/Mnk2 kinase inhibition reduced p38-MAPK phos-
phorylation on the known MEK3/MEK6 phosphorylation sites
T180 and Y182, similar to its effect on eIF4E S209 phosphoryla-
tion (Figure S6B). Finally, we examined p38 phosphorylation in
immortal breast and breast cancer cell lines and observed that
in the latter (which tend to express lower Mnk2a levels) (Fig-
ure 1B), both p38-MAPK and eIF4E phosphorylation is lower
than in the nontransformed cells (Figures S6C–S6E).
We next examined whether Mnk2 isoforms can differentially
interact with p38a-MAPK in cells. Coimmunoprecipitation of
transfected or endogenous p38a from HEK293 cells demon-
strated that Mnk2a and Mnk2aKD, unlike Mnk2b, efficiently
bound p38a (Figure 4B). Importantly, even though Mnk2aKD
was bound to p38a, it did not cause activation of p38a, as
measured by p38a or MK2 phosphorylation (Figures 3D, S5E,
and 4A). Finally, to rule out the possibility that Mnk2 isoforms
compete with Mnk1 for p38a binding, we examined Mnk1 bind-
ing to p38a. Mnk1 was bound to HA-p38a; however, its binding
was not affected by any of the Mnk2 isoforms (Figure 4B). Taken
together, these results suggest that Mnk2a interacts with p38a
and leads to its activation.
Several p38-MAPK isoforms other than p38a exist and are
involved in stress signaling and apoptosis (Cuadrado and
Nebreda, 2010; Turjanski et al., 2007). Thus, we examined if
Mnk2a enhances the phosphorylation of other p38-MAPK family
members when cotransfected into HeLa cells. We found that
Mnk2a enhanced the phosphorylation of p38a and p38b, only
weakly elevated phosphorylation of p38g, and had no significant
effect on phosphorylation of p38d (Figure S6F). We next exam-
ined the interaction of Mnk2a with the other p38-MAPK mem-
bers by coimmunoprecipitation. In correlation with the ability of
Mnk2a to phosphorylate the different p38-MAPK isoforms, we
found that Mnk2a interacts with p38a and p38b, but we could
not detect interaction with p38g or p38d (Figures S6G and
S6H). These results suggest that Mnk2a kinase activity is spe-
cific to p38a and p38b.
Cotransfection of HeLa cells with p38a and WT Mnk2a
showed higher p38a phosphorylation levels than cells co-
transfected with WT MKK3, indicating that (without upstream
activation) Mnk2a’s ability to phosphorylate p38a is as strong
or stronger than MKK3 (Figure 4C). To examine if Mnk2a can
directly phosphorylate p38-MAPK in the absence of the known
p38-MAPK kinasesMKK3 andMKK6 (Enslen et al., 1998; Rinco´n
and Davis, 2009), we transduced MEF cells from MKK3/MKK6
DKO mice (Brancho et al., 2003) with retroviruses encoding for
Mnk2a or an empty vector. Mnk2a induced p38-MAPK phos-
phorylation in the absence of MKK3 and MKK6, suggesting
that it can directly phosphorylate p38-MAPK (Figure 4D). To
further examine if Mnk2a directly phosphorylates p38-MAPK,
we performed an in vitro kinase assay with recombinant
WT Mnk2a and kinase-dead p38a proteins and found that
Mnk2a can directly phosphorylate p38a-MAPK (Figure 4E).
Taken together, these results suggest that Mnk2a is a direct
p38a-MAPK activator kinase.
Mnk2a Colocalizes with p38-MAPK and Affects Its
Cellular Localization
Upon activation, p38-MAPK is translocated to the nucleus and
phosphorylates transcription factors that mediate some of its
stress response (Aplin et al., 2002; Gong et al., 2010; Pfundt
et al., 2001; Plotnikov et al., 2011). Using cytoplasmic and
nuclear fractionation, as well as immunofluorescent staining,
we observed that both Mnk2a and Mnk2b can be detected in
the nucleus (Figures 4F, S6I, and S7). However, cells that ex-
press Mnk2a showed an increased nuclear fraction of total and
phosphorylated p38-MAPK (Figures 4F, 5B, S6I, S7A, andS7B), indicating that Mnk2a leads to both p38-MAPK activation
and its translocation into the nucleus.
In order to examine if Mnk2a affects p38-MAPK cellular local-
ization, we generated two Mnk2a mutants. In the first mutant
(KKR), we mutated the putative nuclear localization signal of
Mnk2a (69-KKRGKKKKR-77) to KKRGKKAAA, in which the last
KKR was replaced with three alanines (AAA). This mutant is ex-
pected to be mostly cytoplasmic, as was shown for the homolo-
gous mutation in Mnk1(Parra-Palau et al., 2003). In the second
mutant (L/S), we mutated the putative nuclear export signal
(NES) of Mnk2. Although in Mnk1, the NES motif is localized to
a different region (Parra-Palau et al., 2003), we identified a similar
motif (LxxxLxxL) in the C-terminal region of Mnk2 (starting at
amino acid 281 ofMnk2a) andmutated the last two lysines to ser-
ines. Transfection of these mutants into HeLa cells or transduc-
tion into MCF-10A cells showed the expected localization: the
nuclear localization of Mnk2a L/S was enhanced, whereas that
of Mnk2a KKR was decreased, when compared to that of
Mnk2a (Figures 5A and S7).When cotransfected with HA-tagged
or GFP-tagged p38-MAPK, Mnk2a colocalized with p38-MAPK.
Mnk2a L/S rendered p38-MAPK mostly nuclear and colocalized
with it in the nucleus. Mnk2a KKR colocalized with p38-MAPK in
both the cytoplasmandnucleus butwas less nuclear thanMnk2a
(Figures 5A, S7A–S7D, and S7F). Both Mnk2a KKR and the L/S
mutants can interact with HA-tagged and endogenous p38a,
as was demonstrated by coimmunoprecipitation, and can pull
down phospho-p38a (Figure S7E). In addition, the effects of
the L/S and KKR mutants on the localization of endogenous
p38a were similar to their effects on HA-p38 in MCF-10A cells
transduced with retroviruses expressing these mutants (Fig-
ure S7A). Overall, these results suggest that Mnk2a and p38-
MAPK are colocalized in both the cytoplasm and nucleus and
that Mnk2a can affect the cellular localization of p38a-MAPK.
Mnk2a Localization Affects Induction of p38-MAPK
Target Genes and Apoptosis
We next examined the expression of FOS and cyclo-oxygenase
2 (COX-2), both targets of p38-MAPK stress response (Ferreiro
et al., 2010). Expression of both genes was induced in MCF-
10A cells expressing Mnk2a and reduced in cells expressing
Mnk2b or Mnk2aKD (Figure 6A). Moreover, knockdown of
Mnk2a inhibited FOS and COX-2 expression (Figure 6B). Inter-
estingly, whereas Mnk2a L/S could activate p38-MAPK target
genes similarly to Mnk2a, the KKR mutant did not increase the
expression of FOS and COX-2 (Figure 6C). To examine if
Mnk1/Mnk2 kinase activity modulates the expression of p38a
target genes, we treated MCF-10A cells with the Mnk1/Mnk2
kinase inhibitor CGP 57380. Inhibition of Mnk1/Mnk2 kinase
activity, which reduced p38-MAPK phosphorylation (Fig-
ure S6B), also reduced the expression p38-MAPK target genes
(Figure 6D). MEF cells from mice with a DKO of both activators
of p38-MAPK, MKK3 and MKK6 (MKK3/MKK6 DKO), show
very low basal phosphorylation of p38-MAPK compared to WT
cells (Brancho et al., 2003) (Figure 4D). Introduction of Mnk2a
into MKK3/MKK6 DKOMEFs elevated p38-MAPK phosphoryla-
tion (Figure 4D) and also induced the expression of FOS and
COX-2 (Figure 6E). Mnk2b inhibited the expression of FOS and
COX-2 below the basal level (Figure 6A). Mnk2aKD inhibitedCell Reports 7, 501–513, April 24, 2014 ª2014 The Authors 507
AB
Figure 5. Mnk2a Colocalizes with p38-
MAPK and Affects Its Cellular Localization
(A) Immunofluorescence of HeLa cells co-
transfected with either empty pCDNA3 vector or
pCDNA3-based expression vectors for T7-tagged
Mnk2a, Mnk2aL/S, or Mnk2aKKR, together with
pCDNA3-GFP-p38a (WT) as described in Experi-
mental Procedures. T7 tag is red, and GFP-p38a
is green. Right view shows quantification of cyto-
plasmic/nuclear distribution of GFP-p38a in cells
similar to those described (n = 40 for each mutant).
*p% 0.01.
(B) Immunofluorescence of MKK3/MKK6/ MEF
cells transduced with the indicated retroviruses.
T7 tag was stained red, and p38a was stained
green. Right view shows quantification of cyto-
plasmic/nuclear distribution of p38a in cells similar
to those described.( n = 57 for pBABE; n = 47 for
Mnk2a). *p = 9.6 3 1017.the expression of COX-2 and had no effect on the expression of
FOS (Figure 6A). This is possibly due to other regulatory ele-
ments in the FOS promoter making it less responsive to inhibition
of MNK2a, as seen from the kinase inhibitor experiment (Fig-
ure 6D). To examine if Mnk2a localization can affect its proapo-
ptotic activity, we treated cells expressing Mnk2a isoforms and
the KKR and L/S mutants with anisomycin and measured cell
death. We found that whereas Mnk2a and the L/S mutant sensi-
tized cells to apoptosis, the KKR mutant inhibited apoptosis and
did not significantly decrease colony survival, in correlation with
its inability to induce p38a target genes (Figures 6F and S4E).
Taken together, these results indicate that Mnk2a not only acti-
vates p38-MAPK, but it also regulates the expression of p38-
MAPK target genes, altering the transcriptional program of the
cells and leading to induction of apoptosis.
Modulation of MKNK2 Splicing by Splice Site-
Competitive Antisense RNA Oligos Affects Sensitivity to
Apoptosis and Cellular Transformation
To examine if modulation of endogenous MKNK2 alternative
splicing affects the oncogenic properties of cells, we used two508 Cell Reports 7, 501–513, April 24, 2014 ª2014 The Authorsexperimental systems in which Mnk2a/
Mnk2b ratios were altered due to cellular
transformation: MCF-10A cells trans-
formed by oncogenic Ras (Figures S1B
and S1C), and immortal lung bronchial
epithelial cells, BEAS-2B, transformed
by SRSF1 overexpression (Shimoni-
Sebag et al., 2013) (Figure S1H). We
designed Cy5-labeled 20-O-met-RNA
antisense oligos to mask the MKNK2
splice sites, shifting the splicing balance
between Mnk2a and Mnk2b (Figures 7A
and 7B). Elevation of Mnk2a and reduc-
tion of Mnk2b by the oligo that
blocks production of Mnk2b (2b Block)
sensitized cells to anisomycin-induced
apoptosis, reduced colony survival, andinhibited soft agar colony formation in both Ras-transformed
MCF-10A cells (Figure 7) and SRSF1-transformed BEAS-2B
cells (Figure S8). The 2b block oligo also enhanced anisomy-
cin-induced apoptosis of nontransformed MCF-10A cells (Fig-
ure 7G). Elevation of Mnk2b and concomitant reduction of
Mnk2a, by the oligo that competes with Mnk2a intron-exon junc-
tion (2a block), protected Ras-transformed MCF-10A cells and
SRSF1-transformed BEAS-2B cells from anisomycin-induced
apoptosis, and increased colony survival (Figures 7E, 7F, S8E,
and S8F). Introduction of the 2a block oligo also protected non-
transformedMCF-10A cells from anisomycin-induced apoptosis
(Figure 7G). The 2a block oligo did not increase anchorage-inde-
pendent growth in soft agar (Figures 7C, 7D, S8C, and S8D),
probably because cells expressing oncogenic Ras or SRSF1
are already highly invasive and tumorigenic (see Figure 2D for
Ras-transformed and Shimoni-Sebag et al., 2013 for SRSF1-
transformed cells). As in the case of Mnk2a or Mnk2b over-
expression (Figures S4F and S4G), in normal conditions without
stress, modulation ofMKNK2 splicing by the antisense oligos did
not induce apoptosis on its own (Figures S8G and S8H). These
data suggest that manipulation of the endogenous ratios of
A B
C D
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Figure 6. Mnk2a Localization and Kinase
Activity Are Required for Induction of p38a
Target Genes and Apoptosis
(A and B) Quantitative RT-PCR (qRT-PCR) of RNA
from MCF-10A cells transduced either with the
indicated Mnk2 isoforms or Mnk2aKD or with MLP
vectors encoding for shRNAs against Mnk2a iso-
form.
(C) qRT-PCR of RNA from MCF-10A cells trans-
duced with either the indicated Mnk2 isoforms or
the indicated Mnk2a mutants.
(D) qRT-PCR of RNA from serum-starved MCF-
10A cells treated with Mnk1/Mnk2 inhibitor CGP
57380 at the indicated concentrations for 8–10 hr.
(E). qRT-PCR of RNA from MKK3/MKK6/ MEF
cells transduced with the indicated retroviruses.
*p% 0.01.
(F) Trypan blue exclusion assay of MCF-10A cells
described in (C) serum starved for 24 hr and then
treated with 0.5 mM anisomycin for 24 hr (graph).
Bottom panel shows a western blot analysis of the
cells described. Cleaved caspase-3 served as a
marker for apoptosis and b-catenin as a loading
control.Mnk2a and Mnk2b affects the oncogenic potential of cells trans-
formed by Ras and SRSF1.
DISCUSSION
The process of alternative splicing is widely misregulated in
cancer, and many tumors express new splicing isoforms,
which are absent in the corresponding normal tissue (Venables
et al., 2009; Xi et al., 2008). Many oncogenes and tumor suppres-
sors are differentially spliced in cancer cells, and it has been
shown that many of these cancer-specific isoforms contribute
to the transformed phenotype of cancer cells (Srebrow and
Kornblihtt, 2006; Venables, 2004). Here, we have shown that
MKNK2 alternative splicing ismodulated in cancer cells to down-
regulate the expression of the tumor-suppressive isoformMnk2a
and enhance the expression of the pro-oncogenic isoform
Mnk2b. Both splicing isoforms phosphorylate the translation
initiation factor eIF4E. However, only Mnk2a binds to and acti-
vates p38-MAPK, leading to enhanced activation of the p38Cell Reports 7, 501–5stress pathway, induction of its target
genes, and enhanced cell death.
Previously, we identified the splicing
factor SRSF1 (SF2/ASF) as a potent
proto-oncogene and reported MKNK2
as one of its splicing targets (Karni et al.,
2007) (Anczuko´w et al., 2012). Enhanced
expression of SRSF1 reduced the levels
of Mnk2a and increased the levels of
Mnk2b, whereas knockdown of SRSF1
caused a reciprocal change in MKNK2
splicing (Karni et al., 2007) (Anczuko´w
et al., 2012). Here, we found that Mnk2a
is downregulated, whereas in some
cases, Mnk2b is upregulated, and thelevel of SRSF1 is upregulated in breast cancer cell lines and
tumors (Figures 1A–1D). Moreover, oncogenic transformation
by Ras elevated the levels of SRSF1 and induced a shift in
MKNK2 splicing (Figures S1B and S1C). Pancreatic cancer cell
lines harboring mutant K-Ras (such as Panc-1) had elevated
SRSF1 levels and altered MKNK2 splicing compared to a
pancreatic cancer cell line with WT K-Ras (Figures S1D–S1G).
In another model system of oncogenic transformation, by
SRSF1 (Shimoni-Sebag et al., 2013),MKNK2 alternative splicing
was also shifted (Figure S1H), suggesting that changes in
MKNK2 splicing occur upon transformation with oncogenes
such as Ras and SRSF1.
Recently, it has been shown that Mnk2, but not Mnk1, inhibits
protein translation through its negative effect on eIF4G Ser1108
phosphorylation and by inhibiting mammalian target of rapamy-
cin activity (Hu et al., 2012). An earlier study detected similar
effects of Mnk2 on translation (Knauf et al., 2001). These results
suggest that Mnk2 might possess a tumor-suppressive activity
by inhibiting translation, an additional mechanism to the one13, April 24, 2014 ª2014 The Authors 509
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Figure 7. Modulation of MKNK2 Splicing by
Splice Site-Competitive Antisense RNA
Oligos Affects Sensitivity to Apoptosis and
Cellular Transformation
(A) Schematic diagram of splice site-interfering
RNA oligonucleotides. 20-O-methyl RNA oligos are
labeled with Cy5 at the 50 and interfere with U1/U2
binding to the 30 splice site of either exon 14a (2a
Block) or exon 14b (2b Block).
(B) RT-PCR of RNA from Ras-transformed MCF-
10A cells transfected with the indicated Cy5-
labeled antisense 20-O-methyl RNA oligos.
Numbers ± SD represent ratio of Mnk2a/Mnk2b
normalized to that of cells transfected with the
scrambled (Scr) oligo (arbitrarily set at 1) (n = 3).
(C) Soft agar growth assay of cells transfected as
in (B). Colonies in ten fields of each well were
counted, and themean and SD of colonies per well
of three wells are shown (n = 3).
(D) Photographs of representative fields of col-
onies in soft agar obtained as described in (C).
(E) Colony formation assay of cells transfected as
in (B). Average and SD of the number of colonies
per well are shown (n = 3).
(F) Cell survival assay and western blot analysis of
MCF-10A-Ras cells transfected as in (B) incubated
in the presence of anisomycin for 36 hr. Cleaved
caspase-3 (Clv. Casp-3) is a marker for apoptosis,
and b-catenin was used as a loading control.
(G) Cell survival assay and western blot analysis of
MCF-10A cells transfected and treated as in (F).proposed in our study. Analyzing RNA-seq data from hundreds
of tumors from patients with breast, colon, and lung cancer
deposited in the TCGA database, we found that the MKNK2
alternative splicing switch occurs in a significant portion of
breast, lung, and colon tumors (Figures 1E–1G and S1) and is
either weakly correlated or inversely correlated with expression
of several splicing factors from the SR and hnRNP A/B families
(Tables S1–S3). These results suggest that a combinatorial
network of splicing factors (rather than a single splicing factor)
controls MKNK2 alternative splicing in tumors. Upregulation of
oncogenic-splicing factors such as SRSF1 can be caused by
several mechanisms such as gene amplification (Karni et al.,510 Cell Reports 7, 501–513, April 24, 2014 ª2014 The Authors2007) or transcriptional activation (Das
et al., 2012) and may lead to a change in
MKNK2 alternative splicing as has been
shown previously (Karni et al., 2007).
To elucidate the role of Mnk2-splicing
isoforms in cancer development, we
examined the oncogenic activity of
Mnk2-splicing isoforms in vitro and
in vivo. Results of these experiments
suggest that Mnk2a possesses a tumor-
suppressive activity in vitro and in vivo,
and this activity of Mnk2a is mediated
by activation of the p38-MAPK pathway.
Interestingly, both Mnk2a and Mnk2b,
but not the Mnk2aKD, phosphorylated
eIF4E to a similar extent, suggestingthat eIF4E phosphorylation cannot account for their different
biological activity (Figures 4A, S3A, and S3C). In cancer cells,
when alternative splicing results in reduced expression of
Mnk2a and increased expression of Mnk2b or when it is manip-
ulated artificially, as we have done here, there is still phos-
phorylation of eIF4E (Figures 3D and 4A), but no activation of
the p38-MAPK pathway, which is mediated by Mnk2a. Thus,
our results suggest that Mnk2b uncouples eIF4E phosphoryla-
tion from activation of the p38-MAPK stress pathway and thus
sustains only the pro-oncogenic arm of the pathway (Figures 3,
4, S5, and S6). However, we cannot rule out the possibility that
Mnk2b can phosphorylate other substrates (yet to be found)
that contribute to its oncogenic activity and, in this manner, acts
as a pro-oncogenic factor. We further found that Mnk2 isoforms
can differentially interact with p38a-MAPK in cells. In coimmuno-
precipitation assays, Mnk2a binds p38a, whereas Mnk2b does
not bind p38a efficiently, suggesting that this interaction might
be important for p38a activation by Mnk2a (Figure 4B). The
ability of Mnk2a to phosphorylate p38-MAPK was similar in
strength or even stronger than MKK3 (Figure 4C), and Mnk2a
can induce p38-MAPK phosphorylation in the absence of
MKK3 and MKK6 (Figure 4D). These results combined with the
results of an in vitro kinase assay (Figure 4E) suggest that
Mnk2a is a direct p38a-MAPK activator kinase. To the best of
our knowledge, Mnk2a is the first direct kinase, other than
MKK3, MKK6, and MKK4, that can phosphorylate and activate
p38-MAPK. Some scaffold proteins can enhance p38-MAPK
autophosphorylation and induce its activation (De Nicola et al.,
2013). However, this cannot explain our finding because we
used a kinase-dead recombinant p38a and recombinant
Mnk2a in the in vitro kinase assay (Figure 4E). We also found
that Mnk2a can bind and phosphorylate both p38a and p38b,
but not p38g or p38d, suggesting that Mnk2a has specificity to-
ward these two substrates (Figures 4A, 4B, and S6F–S6H).
We further confirmed that the kinase activity of Mnk2a is
required for activation of p38a and its target genes because
both the Mnk2aKD or application of the Mnk1/Mnk2 kinase
inhibitor CGP 57380 (Knauf et al., 2001; Chrestensen et al.,
2007) inhibited these activities (Figures S6B and 6). Taken
together, these results indicate that Mnk2 kinase activity is
required for the activation of p38-MAPK and its downstream
targets.
In all of our experimental systems, we demonstrated that
whereas both p38 phosphorylation and eIF4E phosphorylation
are enhanced by Mnk2a overexpression and reduced by its
knockdown, only p38 phosphorylation correlates with the de-
gree of apoptosis (Figure 3). Results from these gain- and loss-
of-function experimental systems suggest that p38-MAPK, but
not eIF4E, phosphorylation/activation determines the fate of
these cells. Finally, in the breast cancer cell lines examined in
this paper, there are lower levels of p38 (and of eIF4E) compared
with two immortal breast cell lines (Figure S6), suggesting clinical
relevance of these findings. The role of the tumor suppressor
activity of p38a was recently demonstrated in hepatocellular
carcinoma and colon cancer development. In both cases,
tissue-specific knockout of p38a led to cancer development
in vivo (Sakurai et al., 2013) (Wakeman et al., 2012). Moreover,
a recent study showed that the gene encoding MKK3, a known
p38-MAPK upstream kinase, is lost in some breast tumors and
that MKK3 acts as a tumor suppressor in breast cancer (MacNeil
et al., 2014). Because Mnk2a acts as another p38-MAPK kinase,
it is reasonable to assume that it acts as a tumor suppressor in a
similar manner.
The generation of Mnk2a mutants mutated in either the NLS
or NES allowed us to examine if Mnk2a affects p38-MAPK
cellular localization and if this effect mediates p38a activation.
When cotransfected with HA-tagged or GFP-tagged p38-
MAPK, Mnk2a colocalized with p38-MAPK both in the cyto-
plasm and nucleus (Figures 5A and S7C). However, transduction
of MKK3//MKK6/ MEFs where p38-MAPK is unphosphory-lated (Figure 4D) with Mnk2a induced nuclear accumulation
of p38-MAPK (Figure 5B). These results suggest that physiolog-
ical expression levels of Mnk2a can induce translocation of
the endogenous p38-MAPK into the nucleus. Both Mnk2a
mutants can interact with p38a, including with its phosphory-
lated form, as was measured by coimmunoprecipitation (Fig-
ure S7E). However, onlyMnk2a and the nuclear L/Smutant could
activate both p38-MAPK target genes (Figure 6C) and induce
apoptosis (Figure 6F), whereas the cytoplasmic mutant KKR
could not activate either and even reduced apoptosis below
the empty vector levels (Figures 6C and 6F). These results sug-
gest that Mnk2a’s ability to translocate p38a into the nucleus
is both required and sufficient to mediate its tumor suppressor
activity as an inducer of p38a-MAPK target genes and
apoptosis. Mnk2b inhibited the expression of FOS and COX-2
below the basal level. Because Mnk2b does not bind p38a, we
hypothesize that it does not act in a dominant-negative manner
to Mnk2a. Rather, other downstream effects of this isoform
may affect the promoters of FOS and COX-2 to inhibit their tran-
scription. Further investigation is required to examine this
question.
WemanipulatedMKNK2 alternative splicing by antisense RNA
oligonucleotides that mask either the Mnk2a or theMnk2b splice
sites (Figure 7A). Results from these experiments suggest that
manipulation of the endogenous ratios of Mnk2a and Mnk2b
affects the oncogenic potential of cells transformed by Ras
and SRSF1. Moreover, these results suggest that MKNK2 alter-
native splicing is a critical event in both Ras- and SRSF1-induced
transformation, similar to other oncogenic alternative splicing
events regulated by SRSF1 (Ben-Hur et al., 2013).
An alternative splicing switch to eliminate a tumor suppressor
is fast and cost effective and serves as an additional level of
regulation. Several examples of such regulation of important
tumor suppressors already exist: BIN1, MDM2, Caspase-9,
BCL-2 family members, and others (Bae et al., 2000; Ge et al.,
1999; Hossini et al., 2006; Kim et al., 2008; Srinivasula et al.,
1999; Steinman et al., 2004). Many tumor suppressor genes
are deleted from the genomes of cancer cells. Such an event
would be unfavorable in the case of Mnk2 because absence of
both isoforms would result in reduced eIF4E phosphorylation,
and cells would be less oncogenic as in the case of Mnk1/
Mnk2-DKO cells (Furic et al., 2010; Ueda et al., 2010). However,
eliminating only Mnk2a and expressing Mnk2b instead would
sustain eIF4E phosphorylation without activation of the p38
stress pathway. Although we did not analyze MKNK2 DNA
copy number variation in tumors, we expect that the main mech-
anism to eliminateMnk2a in tumors will be throughmodulation of
alternative splicing rather than deletion of the MKNK2 gene.
In conclusion, we have identified amechanism inwhichMnk2a
interacts with, phosphorylates, and induces translocation of
p38-MAPK into the nucleus, and thus induces transcription of
its target genes, which results in increased apoptosis. Both
Mnk2a and Mnk2b phosphorylate eIF4E on serine 209, which
contributes to cellular transformation, but Mnk2b, which cannot
bind p38-MAPK, uncouples this phosphorylation from induction
of the p38-MAPK stress response. Our results identify Mnk2
alternative splicing as a mechanism for elimination of a tumor
suppressor (Mnk2a), which is a modulator of the p38-MAPKCell Reports 7, 501–513, April 24, 2014 ª2014 The Authors 511
stress pathway, and for generating the pro-oncogenic isoform
(Mnk2b).
EXPERIMENTAL PROCEDURES
Animal Care
All animal experiments were performed in accordance with the guidelines of
the Hebrew University committee for the use of animals for research. Veteri-
nary care was provided to all animals by the Hebrew University animal care
facility staff in accord with AAALAC standard procedures and as approved
by the Hebrew University Ethics committee.
In Vitro Kinase Assay
In vitro kinase assay was performed using recombinant Mnk2, eIF4E (Abcam),
and kinase-dead p38a (Diskin et al., 2007) as described by Askari et al. (2007)
and Avitzour et al. (2007). In brief, 300 ng of recombinantMnk2awas incubated
alone or with either 5 mg of recombinant kinase-dead p38a or 1 mg of recom-
binant eIF4E, in 20 ml reaction buffer containing 20 mM cold ATP, 0.5 mCi 32P
ATP, 30 mM MgCl2, 10 mM HEPES (pH 7.5), 50 mM EGTA, 10 mM b-glycer-
ophosphate, 5 mM NaVO4, 50 mM b-mercaptoethanol, and 0.5 mM dithio-
threitol (DTT). Reactions were shaken for 1 hr at 30C. Reactions were stopped
by the addition of 50 ml of cold dialysis buffer (12.5 mM HEPES [pH 7.5],
100 mM KCL, 0.5 mM DTT, and 6.25% glycerol) followed by the addition of
30 ml 43 Laemmli buffer. A total of 20 ml of the final volume was separated
by SDS-PAGE, transferred to nitrocellulose by western blotting, and exposed
to Fuji phosphorimager. After the radioactive exposure, the membrane was
probed with the indicated antibodies to visualize the recombinant proteins in
the reaction.
Modulation of MKNK2 Splicing by Antisense-RNA Oligos
Cy5-labeled 20-O-methyl-modified RNA oligonucleotides were synthesized by
Sigma-Aldrich. A total of 2.5 mM of each oligo was transfected using Lipofect-
amine 2000 according to the manufacturer’s instructions. For determination of
RNA levels, BEAS-2B, MCF-10A-Ras, or MCF-10A cells were harvested 48 hr
after transfection, and levels of Mnk2a and Mnk2b were analyzed by RT-PCR.
For biological assays (colony survival, soft agar, and apoptosis), cells were
transfected as described and 24 hr after transfection were seeded for the indi-
cated assay. Oligo sequences, cell lines, plasmids, shRNA, primer sequences,
and additional experimental procedures used are described in Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.03.041.
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